Seaport Therapeutics (SPTX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.78
- Estimate
- -$0.66
- Surprise
- -171.2%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Seaport Therapeutics (SPTX) reported a wider loss than forecast — diluted EPS of -$1.78 against the -$0.66 estimate (a 171.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates SPTX Sell at 5.4/10; no pre/post engine snapshot brackets this report.
0 of the last 2 quarters beat the estimate; this quarter's -171.2% surprise compares with a -168.7% four-quarter average.
What argues against it
- Quality below floor (2.5 < 4.0)
- Momentum score 2.7/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $24.57
- Price target
- $32.19
- Stop
- $22.99
- Upside to target
- +31.0%
- Reward-to-risk
- 2.0:1
Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.
SPTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.33B
- P/E (fwd)
- -9.7
- 52-week range
- $14.85–$28.38
- Off 52-week high
- 13.4%
- RSI (14)
- 52
- Volume vs avg
- 0.31×
- Score today
- 5.4/10